Sponsored content brought to you by
Even for most of modern medicine, the beginning of a disease is synonymous with symptoms. A patient forgets names. Blood sugar rises. Muscles weaken. Only then does diagnosis begin. At the molecular level, though, many diseases start much earlier—sometimes years before symptoms emerge.
Garage Brain Science (GBS), a Taiwan-based biotechnology company focused on asymptomatic-stage screening and intervention, is working to move medicine toward that earlier starting line. Its research focuses on detecting subtle molecular signals that appear before disease becomes clinically visible.
The company recently announced new clinical-research collaborations to support the development of two investigational rapid screening technologies, which might eventually be available for at-home testing. One targets early metabolic stress associated with prediabetes. The other focuses on structural abnormalities in a protein called TDP-43, which is strongly linked to several neurodegenerative diseases.
Together, these programs reflect a broader vision: identifying disease processes during the silent phase when the most effective intervention might still be possible.
Beyond traditional risk factors
Historically, preventive medicine emphasized population-level risks, such as smoking, obesity, or hypertension. Although important, these factors do not necessarily reveal whether disease processes have already begun inside the body.
Instead, GBS focuses on molecular signals—particularly protein misfolding and abnormal biomolecular condensation, such as an irregular clump of proteins. These processes can occur long before measurable physiological changes appear.
For metabolic disease, as an example, many conventional tests detect problems only after dysfunction has progressed. Common examples include measuring the percentage of hemoglobin in the blood that is bound to glucose—hemoglobin A1c (HbA1c) testing—or glucose levels in the blood after not eating—fasting blood-glucose testing. GBS’s investigational prediabetes screening strategy aims to identify earlier stress signals, including patterns associated with islet amyloid polypeptide (IAPP), a protein involved in pancreatic biology.
Initial feasibility work by GBS has been conducted using blood-based assays, and a prototype urine-based format has shown proof-of-concept for potential at-home screening.
Predicting neurodegeneration and more
TDP-43 (TAR DNA-binding protein 43) is a central focus of GBS’s neurodegeneration research. Under normal conditions, TDP-43 is involved in RNA processing and gene regulation and is primarily located in the cell nucleus. In several neurological diseases, however, the protein begins to behave abnormally.
TDP-43 can misfold, accumulate into aggregates, and shift from the nucleus into the cytoplasm of cells. These structural changes disrupt cellular function and are widely recognized as hallmarks of conditions including amyotrophic lateral sclerosis (ALS), certain forms of frontotemporal dementia (FTD), and limbic-predominant age-related TDP-43 encephalopathy (LATE). All of these molecular abnormalities can develop long before patients experience noticeable neurological symptoms.
GBS is developing screening approaches designed to detect signals associated with TDP-43 structural abnormalities in biofluids, such as blood, aiming to move the evaluation of neurodegenerative risk further upstream.
Interpretable disease trajectories
Beyond individual assays, GBS is also building a broader analytical framework called Disease Origin, an AI-driven platform designed to interpret molecular condensation signatures across multiple proteins. Instead of generating a simple binary output, the platform is intended to integrate protein-pattern information with immune and metabolic context. In this framework, screening is not viewed as a one-time snapshot, but as part of a more structured view of disease trajectory, including whether follow-up might be warranted and when additional evaluation might be appropriate.
GBS hopes that combining multi-protein analysis with longitudinal monitoring will provide a clearer understanding of disease trajectories.
Rethinking when medicine begins
To support the development and validation of its technologies, GBS has initiated clinical collaborations with institutions including the National Taiwan University Hospital and the Mayo Clinic. The company is also planning regulatory pathways aligned with potential future deployment in the United States.
For now, the screening technologies remain investigational. Nonetheless, the broader scientific idea behind the work is gaining traction: diseases often begin years before symptoms appear. If those early molecular signals can be detected reliably, medicine might eventually shift from treating established illness to identifying disease at its earliest biological origin.
Learn more about AI-enabled asymptomatic medicine at bit.ly/3PmjxNp.
